Microcap Ledger Corbus Pharmaceuticals Holdings, Inc. $CRBP
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Norwood, MA
- Fiscal year end
- December 31
- Shares outstanding
- 19,341,293 [10-Q 2026-08-06]
What the company doesAI summary of filing
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies in oncology and obesity. The company's lead program, CRB-701, is a Nectin-4-targeting antibody drug conjugate in Phase 1/2 development for head and neck squamous cell carcinoma, cervical cancer, and urothelial cancer; it has received fast track designation from the FDA for cervical cancer and HNSCC indications. CRB-913, a CB1 receptor inverse agonist, is in Phase 1b development for obesity treatment and completed a Phase 1a safety study in December 2025. The company does not generate product revenue and relies on third-party manufacturers for drug supply; it incurred $70.1 million in research and development expenses in 2025. [10-K 2026-03-09]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$58.01M | −$55.20M | $23.37M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | — | −$78.54M | −$64.49M | $28.49M | [10-K 2026-03-09] |
| FY ended Dec 2024 | — | −$40.21M | −$41.79M | $17.20M | [10-K 2026-03-09] |
- Quarterly cash burn
- −$27.60M
- Cash runway Estimate
- ~2.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 12,179,482 | [10-Q 2024-11-07] |
| 2025-03-07 | 12,232,228 | [10-K 2025-03-11] |
| 2025-05-02 | 12,236,767 | [10-Q 2025-05-06] |
| 2025-08-01 | 12,255,225 | [10-Q 2025-08-05] |
| 2025-11-07 | 17,553,037 | [10-Q 2025-11-12] |
| 2026-03-06 | 17,736,464 | [10-K 2026-03-09] |
| 2026-05-08 | 18,527,795 | [10-Q 2026-05-12] |
| 2026-08-04 | 19,341,293 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-03-11; declared effective 2026-03-20 [S-3 2026-03-11]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-14 | Ben Yong | sell | 2,000 | $7.84 | [4 2026-09-15] |
| 2026-08-16 | Nicacio Leonardo Viana | grant | 58,333 | — | [4 2026-08-17] |
| 2026-08-11 | Saxena Nishant C | buy | 2,600 | $9.63 | [4 2026-08-12] |
| 2026-08-07 | Cohen Yuval | sell | 17,000 | $10.08 | [4 2026-08-10] |
| 2026-08-07 | Moran Sean F. | sell | 12,000 | $10.08 | [4 2026-08-10] |
| 2026-06-10 | Kung Winston | sell | 2,026 | $7.91 | [4 2026-06-11] |
| 2026-06-10 | Altmeyer Anne | sell | 2,412 | $7.91 | [4 2026-06-11] |
| 2026-06-10 | Jenkins John Kenneth | sell | 4,800 | $7.91 | [4 2026-06-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-14 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-07 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-07-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-06 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-05-26 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-21 | 8-K | Material agreement entered; Director or officer change; Regulation FD disclosure |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 8-K | Director or officer change; Shareholder vote results; Regulation FD disclosure |
Alerts for $CRBP
Email me when Corbus Pharmaceuticals Holdings, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.